Context Therapeutics
Stock Forecast, Prediction & Price Target
Context Therapeutics Financial Estimates
Context Therapeutics Revenue Estimates
Context Therapeutics EBITDA Estimates
Context Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $8.8M Low: $8.8M High: $8.8M avg. 0% |
Net Income
% change YoY
| $-7.43M N/A | $-14.29M -92.25% | $-23.96M -67.69% | Avg: $-24.13M Low: $-5.90M High: $-4.47M avg. -0.72% | Avg: $-33.76M Low: $-7.82M High: $-6.86M avg. -39.88% | Avg: $-9.73M Low: $-9.73M High: $-9.73M avg. 71.15% | Avg: $-12.29M Low: $-12.29M High: $-12.29M avg. -26.22% |
EBITDA
% change YoY
| $-7.31M N/A | $-14.37M -96.49% | $-25.06M -74.37% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.47 N/A | -$0.9 -91.48% | -$1.5 -66.66% | Avg: -$0.34 Low: -$0.37 High: -$0.28 avg. 77.33% | Avg: -$0.47 Low: -$0.49 High: -$0.43 avg. -38.23% | Avg: -$0.61 Low: -$0.61 High: -$0.61 avg. -29.78% | Avg: -$0.77 Low: -$0.77 High: -$0.77 avg. -26.22% |
Operating Expenses
% change YoY
| $7.43M N/A | $14.88M 100.07% | $25.07M 68.48% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Context Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 1.07% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -5.90M, average is -24.13M and high is -4.47M.
What is Context Therapeutics stock revenue growth forecast?
We have gathered data from 3 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Context Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -4.22% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.37, average is -$0.34 and high is $-0.28.
What is the best performing analyst?
In the last twelve months analysts have been covering Context Therapeutics stock. The most successful analyst is Joseph Catanzaro.